Ultragenyx Pharmaceutical (RARE) Receivables - Net (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Receivables - Net for 14 consecutive years, with $121.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 22.42% year-over-year to $121.0 million; the TTM figure through Mar 2026 stood at $121.0 million (up 22.42% YoY), while the FY2025 annual figure was $158.0 million, up 29.51% from the prior year.
• Receivables - Net climbed to $121.0 million in Q1 2026 per RARE's latest filing, from $1.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $124.5 million in Q2 2025 and bottomed at $1.0 million in Q4 2025.
• Historically, Receivables - Net has averaged $74.7 million across 5 years, with a median of $79.3 million in 2023.
• Annual changes were most pronounced in 2023 — Receivables - Net soared 166.87% — and 2025, when it tumbled 99.18%.
• Ultragenyx Pharmaceutical's Receivables - Net stood at $27.5 million in 2022, then jumped by 166.87% to $73.4 million in 2023, then surged by 66.24% to $122.0 million in 2024, then sank by 99.18% to $1.0 million in 2025, then surged by 12000.0% to $121.0 million in 2026.
• Business Quant data shows RARE's Receivables - Net at $121.0 million in Q1 2026, $1.0 million in Q4 2025, and $112.5 million in Q3 2025.